Efficacy and safety of biosimilar infliximab CT-P13 in the treatment of psoriasis and psoriatic arthritis: 1-year follow-up

An Bras Dermatol. 2019 Oct 17;94(4):483-484. doi: 10.1590/abd1806-4841.20198358. eCollection 2019.

Authors

Patricia Shu Kurizky¹, Letícia Oba Galvão², Gladys Aires Martins³

Affiliations

¹ Dermatology Service, Hospital Universitário de Brasília, Universidade de Brasília, Brasília, DF, Brazil.
² Dermatology Service, Hospital Regional da Asa Norte, Brasília, DF, Brazil.
³ Psoriasis Outpatient Clinic, Hospital Universitário de Brasília, Universidade de Brasília, Brasília, DF, Brazil.

No abstract available

Publication types

Evaluation Study
Letter

MeSH terms

Adult
Aged
Aged, 80 and over
Antibodies, Monoclonal / therapeutic use*
Antirheumatic Agents / therapeutic use*
Arthritis, Psoriatic / drug therapy*
Biosimilar Pharmaceuticals / supply & distribution*
Female
Follow-Up Studies
Humans
Infliximab / therapeutic use*
Male
Middle Aged
Psoriasis / drug therapy*
Treatment Outcome

Substances

Antibodies, Monoclonal
Antirheumatic Agents
Biosimilar Pharmaceuticals
CT-P13
Infliximab